{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:04:29Z","timestamp":1792134269404,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-01048-6","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T13:00:17Z","timestamp":1762434017000},"page":"292-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Primary MRI versus PSA-gated scans in Prostate Cancer Screening \u2013 how ready is it for mainstream implementation?"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0239-3844","authenticated-orcid":false,"given":"Jun Heng","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Yong-Zyn","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehena","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Yong Jie","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Vikesh","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Kong Ngai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Chua Lee Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Kok Shi Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min On","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-0635","authenticated-orcid":false,"given":"Lui Shiong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"1048_CR1","unstructured":"Global Cancer Facts & Figures, 5th edition. Atlanta: American Cancer Society, Inc; 2024."},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.7326\/0003-4819-149-3-200808050-00009","volume":"149","author":"K Lin","year":"2008","unstructured":"Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192\u20139.","journal-title":"Ann Intern Med"},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for Prostate Cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901.","journal-title":"JAMA"},{"key":"1048_CR4","unstructured":"Prostate Cancer Screening in Australia: Position Statement [Internet]. Australian Government Department of Health and Aged Care; 2023. Available from: https:\/\/www.health.gov.au\/resources\/publications\/prostate-cancer-screening-position-statement?language=en"},{"key":"1048_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. 2014;65:1046\u201355.","journal-title":"Eur Urol"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ejca.2007.06.002","volume":"43","author":"S Carlsson","year":"2007","unstructured":"Carlsson S, Aus G, Wessman C, Hugosson J. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) \u2013 Results from a prospective, population-based, randomised study. Eur J Cancer. 2007;43:2109\u201316.","journal-title":"Eur J Cancer"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic Review of Complications of Prostate Biopsy. Eur Urol. 2013;64:876\u201392.","journal-title":"Eur Urol"},{"key":"1048_CR8","doi-asserted-by":"crossref","unstructured":"Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Urology Group, editor. Cochrane Database Syst Rev. 2019. Available from: http:\/\/doi.wiley.com\/10.1002\/14651858.CD012663.pub2","DOI":"10.1002\/14651858.CD012663.pub2"},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bju.15277","volume":"127","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Padhani AR. Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int. 2021;127:175\u20138.","journal-title":"BJU Int"},{"key":"1048_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bju.15118","volume":"126","author":"AYM Lee","year":"2020","unstructured":"Lee AYM, Yang XY, Lee HJ, Law YM, Huang HH, Lau WKO, et al. Multiparametric MRI-ultrasonography software fusion prostate biopsy: initial results using a stereotactic robotic-assisted transperineal prostate biopsy platform comparing systematic vs targeted biopsy. BJU Int. 2020;126:568\u201376.","journal-title":"BJU Int"},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ajur.2018.05.008","volume":"6","author":"EJ Aslim","year":"2019","unstructured":"Aslim EJ, Law YM, Tan PH, Allen JC, Cheng LTE, Chidambaram VA, et al. Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population. Asian J Urol. 2019;6:256\u201363.","journal-title":"Asian J Urol"},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","volume":"10","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Shim SR, Basile G, Baboudjian M, K\u00f3i T, Przydacz M, et al. Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024;10:745.","journal-title":"JAMA Oncol"},{"key":"1048_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018;319:883.","journal-title":"JAMA"},{"key":"1048_CR14","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias Visualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361.","journal-title":"Res Synth Methods"},{"key":"1048_CR16","unstructured":"EndNote [computer program]. Version 20.6 [Internet]. Clarivate; 2023. Available from: https:\/\/www.endnote.com\/"},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.eururo.2015.12.006","volume":"70","author":"A Grenabo Bergdahl","year":"2016","unstructured":"Grenabo Bergdahl A, Wilder\u00e4ng U, Aus G, Carlsson S, Damber JE, Fr\u00e5nlund M, et al. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the G\u00f6teborg Randomised Screening Trial. Eur Urol. 2016;70:566\u201373.","journal-title":"Eur Urol"},{"key":"1048_CR18","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J, Axcrona U, Carlsson SV, Egevad L, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med. 2022;387:2126\u201337.","journal-title":"N Engl J Med"},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bju.15683","volume":"130","author":"A Rannikko","year":"2022","unstructured":"Rannikko A, Leht M, Mirtti T, Kentt\u00e4mies A, Tolonen T, Rinta-Kiikka I, et al. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. BJU Int. 2022;130:193\u20139.","journal-title":"BJU Int"},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","volume":"22","author":"T Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22:1240\u20139.","journal-title":"Lancet Oncol"},{"key":"1048_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","volume":"85","author":"O Bratt","year":"2024","unstructured":"Bratt O, Godtman RA, Jiborn T, Wallstr\u00f6m J, Akre O, Carlsson S, et al. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Eur Urol. 2024;85:207\u201314.","journal-title":"Eur Urol"},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bju.16143","volume":"133","author":"M Alterbeck","year":"2024","unstructured":"Alterbeck M, Thimansson E, Bengtsson J, Baubeta E, Zackrisson S, Bolejko A, et al. A pilot study of an organised population-based testing programme for prostate cancer. BJU Int. 2024;133:87\u201395.","journal-title":"BJU Int"},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euros.2022.01.010","volume":"38","author":"M Wald\u00e9n","year":"2022","unstructured":"Wald\u00e9n M, Aldrimer M, Lagerl\u00f6f JH, Eklund M, Gr\u00f6nberg H, Nordstr\u00f6m T, et al. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. Eur Urol Open Sci. 2022;38:32\u20139.","journal-title":"Eur Urol Open Sci"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","volume":"331","author":"A Auvinen","year":"2024","unstructured":"Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kentt\u00e4mies A, et al. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA. 2024;331:1452.","journal-title":"JAMA"},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.euo.2023.07.006","volume":"6","author":"J Freds\u00f8e","year":"2023","unstructured":"Freds\u00f8e J, Sandahl M, Vedsted P, Jensen JB, Ulh\u00f8i BP, Borre M, et al. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-na\u00efve Population. Eur Urol Oncol. 2023;6:484\u201392.","journal-title":"Eur Urol Oncol"},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.euf.2024.02.006","volume":"10","author":"C Wetterauer","year":"2024","unstructured":"Wetterauer C, Matthias M, Pueschel H, Deckart A, Bubendorf L, Mortezavi A, et al. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING). Eur Urol Focus. 2024;10:332\u20138.","journal-title":"Eur Urol Focus"},{"key":"1048_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.juro.2016.01.114","volume":"196","author":"RK Nam","year":"2016","unstructured":"Nam RK, Wallis CJD, Stojcic-Bendavid J, Milot L, Sherman C, Sugar L, et al. A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. J Urol. 2016;196:361\u20136.","journal-title":"J Urol"},{"key":"1048_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","volume":"6","author":"D Eldred-Evans","year":"2023","unstructured":"Eldred-Evans D, Tam H, Sokhi H, Padhani AR, Connor M, Price D, et al. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study. Eur Urol Oncol. 2023;6:295\u2013302.","journal-title":"Eur Urol Oncol"},{"key":"1048_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00330-023-10019-1","volume":"34","author":"E Messina","year":"2023","unstructured":"Messina E, La Torre G, Pecoraro M, Pisciotti ML, Sciarra A, Poscia R, et al. Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial\u2014Prostate Cancer Secondary Screening in Sapienza (PROSA). Eur Radio. 2023;34:204\u201313.","journal-title":"Eur Radio"},{"key":"1048_CR30","doi-asserted-by":"publisher","first-page":"e059482","DOI":"10.1136\/bmjopen-2021-059482","volume":"12","author":"R Nam","year":"2022","unstructured":"Nam R, Patel C, Milot L, Hird A, Wallis C, Macinnis P, et al. Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. BMJ Open. 2022;12:e059482.","journal-title":"BMJ Open"},{"key":"1048_CR31","unstructured":"Boschheidgen M, Albers P, Schlemmer HP, Hellms S, Bonekamp D, Sauter A, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol. 2023 Oct;S0302283823031585."},{"key":"1048_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/15579883231161292","volume":"17","author":"XL Zhu","year":"2023","unstructured":"Zhu XL, Tung TH, Li H, Wu S, Wang X, Wang L, et al. Using \u201cAge and Total-PSA\u201d as the Main Indicators: The Results of Taizhou Integrated Prostate Screening (No 2). Am J Mens Health. 2023;17:15579883231161292.","journal-title":"Am J Mens Health"},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.15537\/smj.2017.7.18643","volume":"38","author":"MA Arafa","year":"2017","unstructured":"Arafa MA, Farhat KH, Al-Atawi MA, Rabah DM. Prostate cancer screening in a low prevalence population: Is it worth it?. Saudi Med J. 2017;38:733\u20137.","journal-title":"Saudi Med J"},{"key":"1048_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02230-y","volume":"20","author":"SWD Merriel","year":"2022","unstructured":"Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20:54.","journal-title":"BMC Med"},{"key":"1048_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canep.2017.12.002","volume":"52","author":"J Leal","year":"2018","unstructured":"Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, et al. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiol. 2018;52:99\u2013105.","journal-title":"Cancer Epidemiol"},{"key":"1048_CR36","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0022-5347(05)67809-3","volume":"163","author":"FH Schr\u00f6der","year":"2000","unstructured":"Schr\u00f6der FH, Van Der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol. 2000;163:806\u201312.","journal-title":"J Urol"},{"key":"1048_CR37","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level \u22644.0 ng per Milliliter. N Engl J Med. 2004;350:2239\u201346.","journal-title":"N Engl J Med"},{"key":"1048_CR38","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"1048_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re O, Puech P, Renard-Penna R, Claudon M, Roy C, M\u00e8ge-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100\u20139.","journal-title":"Lancet Oncol"},{"key":"1048_CR40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.euo.2023.08.011","volume":"7","author":"R Hogenhout","year":"2024","unstructured":"Hogenhout R, Remmers S, Van Slooten-Midderigh ME, De Vos II, Roobol MJ. From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life. Eur Urol Oncol. 2024;7:713\u201320.","journal-title":"Eur Urol Oncol"},{"key":"1048_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamaoncol.2022.5252","volume":"9","author":"S Hao","year":"2023","unstructured":"Hao S, Discacciati A, Eklund M, Heintz E, \u00d6stensson E, Elfstr\u00f6m KM, et al. Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study. JAMA Oncol. 2023;9:88.","journal-title":"JAMA Oncol"},{"key":"1048_CR42","doi-asserted-by":"publisher","first-page":"e2344856","DOI":"10.1001\/jamanetworkopen.2023.44856","volume":"6","author":"H Yun","year":"2023","unstructured":"Yun H, Kim J, Gandhe A, Nelson B, Hu JC, Gulani V, et al. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results. JAMA Netw Open. 2023;6:e2344856.","journal-title":"JAMA Netw Open"},{"key":"1048_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/jmri.27283","volume":"53","author":"T Tamada","year":"2021","unstructured":"Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, et al. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. J Magn Reson Imaging. 2021;53:283\u201391.","journal-title":"J Magn Reson Imaging"},{"key":"1048_CR44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.09.035","volume":"87","author":"JJ Twilt","year":"2025","unstructured":"Twilt JJ, Saha A, Bosma JS, Van Ginneken B, Bjartell A, Padhani AR, et al. Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. Eur Urol. 2025;87:240\u201350.","journal-title":"Eur Urol"},{"key":"1048_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78428-6","volume":"11","author":"YH Fan","year":"2021","unstructured":"Fan YH, Pan PH, Cheng WM, Wang HK, Shen SH, Liu HT, et al. The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer. Sci Rep. 2021;11:1286.","journal-title":"Sci Rep"},{"key":"1048_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.21037\/tau-23-80","volume":"12","author":"B Wu","year":"2023","unstructured":"Wu B, Shao Y, Lin X, Hasi C, Jia W, Wang D, et al. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study. Transl Androl Urol. 2023;12:425\u201332.","journal-title":"Transl Androl Urol"},{"key":"1048_CR47","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","volume":"392","author":"JK McHugh","year":"2025","unstructured":"McHugh JK, Bancroft EK, Saunders E, Brook MN, McGrowder E, Wakerell S, et al. Assessment of a Polygenic Risk Score in Screening for Prostate Cancer. N Engl J Med. 2025;392:1406\u201317.","journal-title":"N Engl J Med"},{"key":"1048_CR48","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3390\/cancers15041280","volume":"15","author":"A Basso Dias","year":"2023","unstructured":"Basso Dias A, Ghai S. Micro-Ultrasound: Current Role in Prostate Cancer Diagnosis and Future Possibilities. Cancers. 2023;15:1280.","journal-title":"Cancers"},{"key":"1048_CR49","doi-asserted-by":"crossref","unstructured":"Kinnaird A, Luger F, Cash H, Ghai S, Urdaneta-Salegui LF, Pavlovich CP, et al. Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA. 2025; Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2831985","DOI":"10.1001\/jama.2025.7944"},{"key":"1048_CR50","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231130","volume":"309","author":"F Giganti","year":"2023","unstructured":"Giganti F, Ng A, Asif A, Chan VWS, Rossiter M, Nathan A, et al. Global Variation in Magnetic Resonance Imaging Quality of the Prostate. Radiology. 2023;309:e231130.","journal-title":"Radiology"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01048-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01048-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01048-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:04:12Z","timestamp":1779343452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01048-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01048-6","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data used in our analysis is publicly available from published studies. As such, no institutional review board (IRB) approval was necessary. This study was not supported by any sources of funding. All authors have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}